# Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

> **NCT04592237** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 120 (estimated)

## Conditions studied

- Aggressive Variant Prostate Carcinoma
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Metastatic Prostate Neuroendocrine Carcinoma
- Metastatic Prostate Small Cell Carcinoma
- Stage IV Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Cabazitaxel
- **DRUG:** Carboplatin
- **BIOLOGICAL:** Cetrelimab
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT04592237
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-29
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04592237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04592237, "Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04592237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*